Paradigm I Clinical Trial: Study of the PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemia Attack or Paradoxical Embolism

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2006 by Cierra.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Cierra
ClinicalTrials.gov Identifier:
NCT00196027
First received: September 12, 2005
Last updated: November 27, 2006
Last verified: November 2006

September 12, 2005
November 27, 2006
April 2005
Not Provided
PFO closure as measured by transesophageal echocardiography (TEE) or transcranial Doppler (TCD) acutely post procedure
PFO closure as measured by TEE or TCD acutely post procedure
Complete list of historical versions of study NCT00196027 on ClinicalTrials.gov Archive Site
  • PFO closure as measured by TEE or TCD at 30 days post procedure
  • Neurological death and adverse event (AE) rates for all subjects through 30 day follow-up
  • New arrhythmia rate through 30 day follow-up. For any subjects with new arrhythmia, arrhythmia status will also be evaluated at a follow-up visit from 3 to 6 months post procedure
  • PFO closure rate at 3 to 6 months for any subject not demonstrating complete closure at the 30 day follow-up
  • PFO closure as measured by TEE or TCD at 30 days post procedure.
  • Neurological death and AE event rates for all subjects through 30 day follow-up
  • New arrhythmia rate through 30 day follow-up. For any subjects with new arrhythmia, arrhythmia status will also be evaluated at a follow-up visit from 3 to 6 months post procedure.
  • PFO closure rate at 3 to 6 months for any subject not demonstrating complete closure at the 30 day follow-up.
Not Provided
Not Provided
 
Paradigm I Clinical Trial: Study of the PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemia Attack or Paradoxical Embolism
Feasibility Study of the PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemia Attack or Paradoxical Embolism

The primary objective of this study is to demonstrate the safety of the PFX Closure System when utilized for patients with patent foramen ovale (PFO) suffering from cryptogenic stroke, transient ischemic attacks or paradoxical embolism.

Patent Foramen Ovale has been implicated in the etiology of paradoxical embolism, cryptogenic stroke, transient ischemic attack (TIA), and right to left gas embolism in severe decompression illness. An association between patent foramen ovale and severe migraine headaches has also been reported. Several implantable devices are being used for percutaneous closure of patent foramen ovale; we propose to use a non-implantable system to safely effect closure.

Interventional
Not Provided
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Patent Foramen Ovale
Device: PFX Closure System
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
40
Not Provided
Not Provided

Inclusion Criteria:

  • Subject is between 18 and 65 years old.
  • Documented patent foramen ovale as determined by positive micro bubble study demonstrating right to left shunt and/or anatomic detection and functional assessment by pre-operative TCD and peri-operative echocardiography or ultrasound.
  • Subjects with a history of cryptogenic stroke, transient ischemic attack or paradoxical embolism due to presumed paradoxical embolism through a PFO.
  • Negative pregnancy test in women who are of child-bearing potential.
  • Signed Informed Consent form.

Exclusion Criteria:

  • Presence of thrombus at the intended site of closure, in left atrial appendage, or documented evidence of venous thrombus in the vessels through which access to the PFO is gained.
  • Active endocarditis, or other infections producing a bacteremia.
  • Presence of atrial septal defects or fenestrations which allow right-to-left shunting.
  • Presence of implanted cardiac valves, pacemaker, implantable cardioverters/defibrillators (ICDs) or vena cava filters.
  • Subjects with an intra-cardiac mass, tumor, clot or vegetation.
  • Large, redundant atrial septal aneurysm that would prohibit adequate device access to the PFO or closure of the PFO, in the judgment of the investigator. A coexisting redundant atrial septal aneurysm is considered large if it prohibits the ability of the operator to adequately achieve vacuum suction necessary to achieve PFO closure.
  • Presence of arrhythmia requiring pharmacologic or electrical therapy intervention or 1st degree block.
  • Current enrollment in any investigational trial(s) using devices implanted in the vascular system or enrolled in any experimental drug study(ies) within three months of study entry.
  • History of stroke or TIA within the past 14 days.
  • Source of stroke other than paradoxical embolization.
  • Hemodynamic instability or shock.
  • Hypercoagulable disorder.
  • Subjects with coagulation disorders who are unable to take antiplatelet or anticoagulant therapy.
Both
18 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT00196027
2005-001 version 1
Not Provided
Not Provided
Cierra
Not Provided
Principal Investigator: Horst Sievert, MD Cardio Vasculares Centrum - Sankt Katharien
Cierra
November 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP